Description: Rabbit polyclonal antibody to MKK1/2 Immunogen: KLH-conjugated synthetic peptide encompassing a sequence within the center region of human MKK1/2. The exact sequence is proprietary. Purification: The antibody was purified by immunogen affinity chromatography. Clonality: Polyclonal Form: Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Dilution: WB (1/500 - 1/1000), IH (1/100 - 1/200) Gene Symbol: MAP2K1; MAP2K2 Alternative Names: MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1; MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein kinase kinase 2; MAP kinase kinase 2; MAPKK 2; ERK activator kinase 2; MAPK/ERK kinase 2; MEK 2Entrez Gene (Human): 5604; 5605Entrez Gene (Mouse) : 26395; 26396Entrez Gene (Rat) : 170851; 58960SwissProt (Human): Q02750; P36507SwissProt (Mouse) : P31938; Q63932SwissProt (Rat) : Q01986; P36506Storage/Stability : Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.
-
Western blot analysis of MKK1/2 expression in HT29 (A), mouse brain (B) whole cell lysates.
-
Immunohistochemical analysis of MKK1/2 staining in human prostate cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer
MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer